Is Ei.Ventures the next big thing in psychedelic medicine? CEO David Nikzad Believes So

December 16, 2020 (Investorideas.com Newswire) Psychedelic medicines have been around for decades, but there has always been a large portion of the world unwilling to give them a try. Regulations have long stood in the way for most, and the reputation of psychedelics since they were classed as Schedule I drugs in 1970 have left many skeptical.

David Nikzad, CEO of a new life science company called Emotional Intelligence Ventures, hopes to change perceptions and introduce people to a new type of alternative medicine. He believes that they are very close to having breakthrough solutions that will help with anything from mild depression to intimacy issues millions face every day.

Why psychedelic research matters to Nikzad

Getting everything right before launch is what will dictate expectations and reputation. This is why Nikzad is willing to put in all the research necessary to compete with any alternative on the market.

Due to psychedelic medicine's nature, the right amount of research needs to go into every potential lead towards an effective solution. There are so many complications that could pop up without doing the right research. Regulations will also be strict, meaning that the proper amount of research time helps gain approval in the first place.

Battling regulation

As great as psychedelic medicine sounds on paper, Nikzad understands that the biggest obstacle at this point comes down to regulation. He has found a way to make solutions as affordable as possible for all, but the regulation process can take months if not years in many situations.

The projections right now have Oregon being one of the first states on the mainland to open up the use of psychedelic medicine. Nikzad already has a plan in place for when that happens, and that could be the first time many people experience the positive effects.

Canada is also a country that is a focus for Nikzad and his company at this moment. They have shown the world that they are becoming more open to different laws and regulations regarding alternative medication. While a specific timetable is unknown at this time, many believe that both Oregon and Canada will have laws in place that will allow for different psychedelic medicines within the next five years.

Nikzad remains hugely optimistic about regulations finally allowing psychedelic medicine to make its impact, but he also knows there is still a lot of work to do with Ei.Ventures. It is not so much a race to be first on the market, but to be the best and most effective. Many companies will eventually try capitalizing on this new market, but the most knowledgeable, well researched, and affordable options will rise to the top.

Specific focus for best results

With a small team at Ei.Ventures, Nikzad believes in focusing on a few breakthroughs instead of trying to spread too thin. Psychedelic medicine helps in many ways, but trying to cure everything at once leads to many subpar products. His team is currently working on three compounds that will serve a particular purpose and instantly be in need. They are alternatives to other medications already on the market, and they have a huge following.

Brain Mana, medicinal mushroom formulation utilizes multiple types of mushrooms that work in a lot of the same ways as Psilly, Ei.Ventures Psilocybin based therapeutic. The difference will be there are no psychoactive compounds in Brain Mana, which focuses more on the health benefits instead of what gives it a negative connotation.

Happy Sexy is the working name for a product that plans to compete directly with Viagra and other sexual enhancement medical solutions. Energy Mana, another nutraceutical Ei plans to be may be an alternative to Adderall. As useful as Adderall can be for many, it has qualities that people are trying to move away from. Having a product that is legal and made entirely out of botanicals can help tremendously without people running into any negative issues.

New round of funding

Nikzad continues to put together a new round of funding and look for individuals interested in helping the movement grow. He understands that there are still many people with questions, and he walks through plans and current breakthroughs for Ei.Ventures to anyone who wants a better understand.

This round of investor funding is important since those all around the world can participate as well. A pathway towards success is mapped out, and preparations are in place once regulations ease up.

The biggest hindrance to psychedelic medicine in the past has been a lack of breakthroughs. Now that companies are receiving funding and there is a light at the end of the tunnel to offer products legally, many are excited about what the future holds.

Nikzad's proven track record with startups

David Nikzad is no stranger to the startup world. He has helped a lot of entrepreneurs throughout the years. He has invested in over 100 companies at this point in his life, helping out smaller companies that might not have the opportunity to get as much funding as they would like. He believes that there are a lot of great ideas out there that fall apart for no other reason than a lack of money.

Along with funding entrepreneur ideas, he also acts as a mentor for individuals going through the startup process for the first time. He is directing the ship with Ei.Ventures, and his experience with startups allows him to tackle any hurdles on the way much better than those lacking experience.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions.

More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. This article is a third party guest post published content and not the content of Investorideas.com. Learn more about posting your articles at http://www.investorideas.com/Advertise/

Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp